|
Indivior PLC - Richmond, Virginia-based pharmaceutical firm - Says its subsidiaries Indivior Inc and Indivior UK Ltd has agreed on a settlement deal with Actavis Laboratories UT Inc, a subsidiary of Teva Pharmaceuticals, resolving patent disputes of Actavis’s abbreviated new drug application for generic buprenorphine and naloxone sublingual film. Says it has granted Actavis a license to US patent no.11,135,216, allowing it to launch general film products in the US from January 31 2025, unless unexpired patent claims are found to be invalid. Current stock price: 1,179.00 pence, up 2.8% on Wednesday 12-month range: down 34% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
